The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Therapeutics for Osteoarthritis May Be in Sight

New Therapeutics for Osteoarthritis May Be in Sight

April 1, 2015 • By Antonios Aliprantis, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Sebastian Kaulitzki/shutterstock.com
Image Credit: Sebastian Kaulitzki/shutterstock.com

“Doctor, I saw a commercial on TV for a new drug to treat arthritis,” is a statement I’ve heard time and again from my patients suffering with osteoarthritis (OA).

You Might Also Like
  • Can Lubricating Joints Prevent Osteoarthritis?
  • EULAR 2013: Researchers Make Inroads in Treatment of Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
Explore This Issue
April 2015

My response is universally the same, “Oooh, that’s not for you; that’s for patients with rheumatoid arthritis.” This then turns into a conversation about the differences between degenerative and autoimmune joint disease. My concluding remark is usually the same, “We don’t have anything new for your arthritis now, but we’re working on it”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Despite the fact that OA is one of the most prevalent diseases among middle-age and older adults, there are few treatment options for OA patients. We all know the therapeutic progression for knee OA, for example: weight loss and exercise, acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroid injections and some physical therapy, now and again. Go back a few decades, and the options were the same.

As we look ahead though, is there reason to believe that new therapeutics to alleviate pain and prevent further joint degeneration are on the horizon? A brief look at the modern understanding of OA progression suggests an emphatic oxymoron, “maybe, yes.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In this article, a brief overview of OA pathogenesis frames recent discoveries suggesting that new strategies for this disease are possible.

OA Pathogenesis

The pathogenesis of OA can be conceptualized as a complex set of interactions that cooperate to promote joint degeneration over time (see Figure 1). Diverse insults can initiate the osteoarthritic process.1 These include joint injury (e.g., ligament or meniscal tears), malalignment, prior episodes of inflammatory arthritis and the aging process itself.

Genetic conditions that affect joint lubrication and type II collagen biochemistry can also instigate OA.2-4 Eventually, a chronic wound-healing response becomes entrenched within the joint.5 Cartilage degradation products aggravate a synovial inflammatory response, which in turn upregulates catabolic enzymes, such as matrix metalloproteinases (MMPs) and cathepsins, further damaging the cartilage matrix.1 The subchondral bone also undergoes profound changes, with accelerated bone turnover early in the disease, followed by necrosis and fibrosis, which can be seen as bone marrow edema-like lesions on MRI. Ultimately, sclerosis and subchondral cysts develop.6

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

These alterations in subchondral bone may influence the mechanical properties of the overlying cartilage perpetuating damage. Inflammation and loss of chondrocytes also reduce synovial fluid and boundary lubricants that may stress cartilage further.7

It is this web of interactions that makes OA a challenge for therapeutic development. However, recent studies suggest that disease-modifying treatments are possible. Here, we look at three possible classes of therapeutics: catabolic enzyme inhibitors, biolubricants and stem cells.

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, Drug Updates, Osteoarthritis Tagged With: Aliprantis, discovery, joint degeneration, Osteoarthritis, Pain, Pathogenesis, Research, TreatmentIssue: April 2015

You Might Also Like:
  • Can Lubricating Joints Prevent Osteoarthritis?
  • EULAR 2013: Researchers Make Inroads in Treatment of Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • Newly Discovered Molecule Modulates Cartilage Repair

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)